Effects of Psilocybin on Anxiety and Psychosocial Distress in Cancer Patients
Interventional
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
anxiety
2-4 weeks prior to drug administration
Yes
Stephen Ross, MD
Principal Investigator
New York University School of Medicine
United States: Food and Drug Administration
06-954
NCT00957359
February 2009
July 2014
Name | Location |
---|---|
NYU College of Dentistry Bluestone Center for Clinical Research | New York, New York 10010 |